Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Ordinary Shares, no par value
-
Shares outstanding
-
182,917,028
-
Total 13F shares
-
67,784,074
-
Share change
-
+20,282,045
-
Total reported value
-
$220,297,785
-
Price per share
-
$3.25
-
Number of holders
-
56
-
Value change
-
+$69,127,143
-
Number of buys
-
21
-
Number of sells
-
55
Institutional Holders of Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE) as of Q2 2022
As of 30 Jun 2022,
Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE) was held by
56 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
67,784,074 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., M28 Capital Management LP, MAVERICK CAPITAL LTD, 683 Capital Management, LLC, Bellevue Group AG, PRIMECAP MANAGEMENT CO/CA/, Artal Group S.A., ADAGE CAPITAL PARTNERS GP, L.L.C., Kynam Capital Management, LP, and BlackRock Inc..
This page lists
56
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.